Companies are deconstructing magic mushroom cocktails in search of therapeutic medicines.
Can the meteoric rise of psychedelics and entactogens clear the legal hurdles of abuse potential assessment and rescheduling?
Psychedelic trips often unfold without issues, but what if a trip needs to be stopped? Drugs such as benzodiazepines and antipsychotics are recommended as rescue medications and have been around for decades. Can ketanserin be used as a more targeted trip stopper?
The serotonin receptor subtype 5-HT2A is key for the effects of many psychedelic substances in humans, but it is also a major drug target for new antidepressants. However, large challenges have prevented this therapeutic promise from being realised. Overcoming the early bottlenecks, innovative drug discovery methods have produced two new compounds with potential for therapeutic development.
The potential neurotoxicity of MDMA led to the development of APBs, a family of entactogens whose effect profiles may position them as attractive candidates for the next generation of entactogenic medicines.
Experts say COMPASS’ analysis overlooked one of the crystal forms present in their sample.
False. Read on to find out how sporulation impacts the potency of Psilocybe cubensis.
Some scientists are skeptical of the entourage effect in psychedelics as research companies are charging ahead with the concept.
Patent filings indicate that CaaMTech was the first company to propose an entourage effect in psychedelic compounds.
This company is approaching psychedelic mushroom research literally from the ground up.